Want to see PEN full AI Analyst Report?
Penumbra (PEN) Stock Price & Analysis
PEN Stock Chart & Stats
- Day’s Range
- $319.03 - $320.72
- 52-Week Range
- $259.14 - $362.41
- Previous Close
- $321.11
- Volume
- N/A
- Average Volume (3M)
- 377.83K
- Market Cap
- $12.58B
- Enterprise Value
- $12.15B
- Total Cash (Recent Filing)
- $673.61M
- Total Debt (Recent Filing)
- $209.39M
- Price to Earnings (P/E)
- 80.0
- Beta
- 0.04
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 1.44
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability Growth
Penumbra is combining rapid revenue expansion with healthy gross and operating profitability, showing that growth is translating into earnings rather than relying solely on volume. This creates greater internal capacity to invest in products, commercial reach, and clinical adoption over the coming quarters.
Conservative Balance Sheet
Low leverage and substantial equity growth provide financial flexibility as Penumbra expands its device portfolio and commercial infrastructure. A conservative capital structure reduces financing pressure, improves resilience during operating volatility, and leaves more options for funding long-term innovation.
Clinical Support For Pulmonary Embolism Expansion
Clinical evidence supporting Penumbra’s computer-assisted vacuum thrombectomy may strengthen physician confidence and broaden adoption in pulmonary embolism treatment. Demonstrated functional and recovery benefits can support durable expansion of the addressable market beyond the company’s established neurovascular franchise.
Bears Say
Margin Compression
Declining net margins indicate that higher revenue is not converting into proportionally higher profitability. Whether driven by costs, product mix, or reinvestment, sustained compression could limit earnings scalability and reduce the financial benefit of otherwise strong growth over the next several quarters.
Free Cash Flow Decline
Positive cash generation supports earnings quality, but the recent free cash flow decline suggests that spending or working-capital requirements are absorbing more of the company’s operating gains. If persistent, this could constrain self-funded investment and weaken the conversion of profit into financial flexibility.
Lower Returns On Equity
The decline in returns on shareholder capital suggests that improving absolute profitability has not fully kept pace with the growth of the equity base. Persistently lower returns could indicate less efficient capital deployment and would make future expansion less productive for shareholders.
Penumbra News
PEN FAQ
What was Penumbra’s price range in the past 12 months?
What is Penumbra’s market cap?
When is Penumbra’s upcoming earnings report date?
How were Penumbra’s earnings last quarter?
Is Penumbra overvalued?
Does Penumbra pay dividends?
What is Penumbra’s EPS estimate?
How many shares outstanding does Penumbra have?
What happened to Penumbra’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Penumbra?
What is the TipRanks Smart Score and how is it calculated?
Penumbra Stock Smart Score
Company Description
Penumbra
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Adam Elsesser
- Employees
- 4,700
- Website
- www.penumbrainc.com
- Address
- One Penumbra Place, Alameda, CA, 94502, US
Penumbra (PEN) Earnings & Revenues
PEN Earnings Call
Earnings Call SentimentPositive
The earnings call reflected a strong performance with significant revenue growth, particularly in the VTE and embolization segments, and positive developments in clinical trials, offset by some challenges in international markets and increased operational costs.
View all PEN earnings summariesPEN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |
